When starting a new medication, patients closely monitor their lab results—and unexpected numbers can cause unnecessary alarm. Testosterone levels do not exist in isolation. Every hormone participates in a larger network, and changes in one pathway often create compensatory changes elsewhere. This principle becomes particularly relevant when discussing medications such as finasteride and related 5-alpha reductase inhibitors. Many patients are surprised to discover that testosterone levels frequently increase after starting these medications, and in some cases, both total and free testosterone rise above the reference range.
This finding often creates confusion. Patients wonder whether the medication is causing hormonal imbalance, whether elevated testosterone is dangerous, or whether treatment should be adjusted. The answer lies in understanding how testosterone normally moves through the body.
Understanding the Testosterone Pathway
Testosterone serves as a precursor hormone. One important pathway converts testosterone into dihydrotestosterone (DHT) through the enzyme 5-alpha reductase. DHT is not a separate hormone produced independently; instead, it originates directly from testosterone.
When medications like finasteride block this enzyme, less testosterone is converted into DHT. Consequently, more testosterone remains available within the circulation rather than moving downstream into the DHT pathway. The result is often a modest increase in measured testosterone levels. This response represents expected physiology rather than an abnormal reaction.
How Common Is Testosterone Elevation?
Clinical studies consistently demonstrate that finasteride increases circulating testosterone levels. Most studies report average increases of approximately 10–30% in total testosterone after treatment begins.
While the magnitude varies considerably among individuals—with some men experiencing minimal changes—others demonstrate more substantial increases that occasionally push laboratory values above the upper reference range. Men who start with lower baseline testosterone often experience larger relative increases because a greater proportion of available testosterone remains unconverted. Free testosterone may also rise, particularly if total testosterone increases substantially or if sex hormone-binding globulin (SHBG) remains stable. Therefore, mildly elevated total or free testosterone during finasteride therapy is not uncommon and frequently reflects the expected pharmacologic effect of treatment.
Common Hormonal Changes Seen During Finasteride Therapy
| Finding During Finasteride Therapy | Why It Happens | Usual Significance |
|---|---|---|
| Total testosterone increases | Less testosterone converts into DHT | Common and usually expected |
| Free testosterone increases | More circulating testosterone remains available | Often mild, especially if SHBG stays stable |
| DHT decreases | 5-alpha reductase activity is blocked | Main intended effect of treatment |
| Testosterone appears “high” | The pathway shifts upstream | Usually not the same as androgen excess |
| Prostate androgen stimulation decreases | DHT falls despite higher testosterone | Often clinically beneficial |
| Scalp androgen exposure decreases | Less DHT reaches hair follicles | Helps slow androgenic hair loss |
| Estradiol may increase slightly | More testosterone may aromatize into estrogen | Usually mild, but symptoms matter |
| Symptoms vary widely | Tissue sensitivity differs by person | Labs need clinical context |
| Marked testosterone elevation | May involve TRT, supplements, lab timing, or other factors | Worth reviewing more carefully |
| Mild isolated elevation | Expected medication effect | Usually does not require intervention |
Why Higher Testosterone Does Not Necessarily Mean Excess Androgen Activity
A common mistake involves viewing testosterone alone while ignoring DHT. Although testosterone may increase, DHT typically decreases substantially. Because DHT possesses greater androgenic potency in certain tissues, particularly the prostate, scalp hair follicles, and skin, this creates an interesting physiologic tradeoff.
Laboratory testing may show higher testosterone, yet overall androgen signaling within specific tissues may actually decrease because DHT production has been suppressed. This explains why patients can simultaneously exhibit:
- Higher testosterone
- Lower DHT
- Reduced prostate stimulation
- Slower androgenic hair loss
At first glance, these findings appear contradictory. However, they become coherent once the entire pathway is considered.
When Elevated Testosterone May Be Beneficial
In many individuals, the increase in testosterone carries little clinical significance beyond laboratory findings. However, some men report subtle improvements in:
- Energy
- Libido
- Recovery
- Sense of well-being
These effects are variable and should not be assumed. Importantly, finasteride is not a testosterone replacement therapy. Any increase generally remains modest compared with changes seen during formal testosterone treatment. Nevertheless, the physiologic shift occasionally provides a small hormonal advantage for some patients.
When Elevated Testosterone Deserves Attention
Most testosterone elevations associated with finasteride require no intervention. However, interpretation becomes more important when levels become substantially elevated or symptoms emerge. Potential considerations include:
- Pre-existing testosterone therapy
- Concurrent use of anabolic agents
- Laboratory timing variations
- Elevated hematocrit
- Acne or increased oil production
- Significant changes in estradiol
Because testosterone can also convert into estrogen through aromatization, a subset of patients may experience increased estradiol levels alongside rising testosterone. This can occasionally contribute to breast tenderness, fluid retention, or other estrogen-related symptoms. In these situations, looking at the broader hormonal picture becomes more valuable than focusing on testosterone alone.
The Importance of Looking Beyond a Single Number
Hormones function within networks rather than isolated laboratory values. A testosterone level that appears elevated may represent a completely different physiologic state depending on accompanying DHT, estradiol, SHBG, symptoms, and overall health.
For example, a man with mildly elevated testosterone and markedly reduced DHT after finasteride differs fundamentally from a man with identical testosterone levels using anabolic steroids. The laboratory number may be similar, but the physiology is not. This distinction illustrates why interpretation requires context.
Why Holistic, Individualized Care Matters
Finasteride often demonstrates an important lesson in endocrinology: hormone levels alone rarely tell the whole story. A rise in testosterone during treatment is common and usually reflects predictable changes in hormone metabolism rather than pathology. The body simply redirects hormone flow after part of the pathway becomes blocked.
The key question is not whether testosterone increased, but rather how the entire hormonal system responded. When clinicians evaluate testosterone, free testosterone, DHT, estradiol, SHBG, symptoms, body composition, and overall health together, the results become far more informative than any single laboratory value alone.
Conclusion
Mild elevations in total or free testosterone occur frequently during finasteride therapy and generally represent a normal pharmacologic effect of reduced testosterone-to-DHT conversion. In most cases, these changes do not require treatment and do not indicate hormonal excess. Instead, they reflect the body’s adaptation to a modified androgen pathway. As with many areas of endocrinology, the significance of the laboratory value depends less on the number itself and more on how that number fits into the larger hormonal landscape.
At our practice in Montgomery County, Maryland, and through virtual care, we frequently evaluate complex hormone patterns by examining the entire endocrine system rather than focusing on a single laboratory marker. This integrated approach often reveals connections that isolated numbers alone cannot explain.
- The Effect of Finasteride in Men with Benign Prostatic Hyperplasia. Gormley GJ, Stoner E, Bruskewitz RC, et al. NEJM. 1992.
- Androgenetic Alopecia: Effects of Oral Finasteride on Hormone Profile, Reproduction and Sexual Function. Pallotti F, Senofonte G, Pelloni M, et al. Endocrine. 2020.
- Effect of Finasteride on Serum Levels of Androstenedione, Testosterone and Their 5α-Reduced Metabolites in Men at Risk for Prostate Cancer. Stanczyk FZ, Azen CG, Pike MC. J Steroid Biochem Mol Biol. 2013.
- Finasteride. Rittmaster RS. NEJM. 1994.
- Effects of the 5 Alpha-Reductase Inhibitor Finasteride on Serum Levels of Gonadal, Adrenal, and Hypophyseal Hormones and Its Clinical Significance: A Prospective Clinical Study. Uygur MC, Arik AI, Altuğ U, Erol D. Steroids. 1998.
- Associations of Serum Sex Steroid Hormone and 5α-Androstane-3α,17β-Diol Glucuronide Concentrations With Prostate Cancer Risk Among Men Treated With Finasteride. Kristal AR, Till C, Tangen CM, et al. Cancer Epidemiol Biomarkers Prev. 2012.
- Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Jayasena CN, Anderson RA, Llahana S, et al. Clin Endocrinol (Oxf). 2022.
About Dr. Gerti Tashko, MD
Dr. Gerti Tashko, MD, is an endocrinologist in Montgomery County, Maryland. He is uniquely quadruple board-certified in endocrinology, lipidology, hypertension, and obesity medicine. His practice delivers root-cause-focused metabolic and endocrine care, available virtually and in person. He uses advanced diagnostics, personalized nutrition, and preventive medicine to improve long-term health.




